Daily James W, Zhang Ting, Cao Shihua, Park Sunmin
1 Department of R&D Daily Manufacturing, Inc. , Rockwell, NC.
2 Department of Food and Nutrition, Institute of Basic Science, Obesity/Diabetes Research Center, Hoseo University , Asan, South Korea .
J Altern Complement Med. 2017 Oct;23(10):756-770. doi: 10.1089/acm.2017.0098. Epub 2017 Jun 13.
GuiZhi-ShaoYao-ZhiMu decoction (GSZD), a traditional Chinese herbal medication for the management of rheumatoid arthritis (RA), has a long history of use and modern scientific research support for efficacy, but the studies have not been systematically evaluated. Therefore, this study systematically reviewed the efficacy of GSZD using the available human clinical trials and conducted a meta-analysis.
The available databases were searched using proper languages of English, Korean, and Chinese. The key erms used for searching were "GSZD," "Cassia Twig," "Guizhi," "Paeonia lactiflora," "Shaoyao," "Anemarrhena Rhizome," "Zhimu," "rheumatoid arthritis," "randomized," "controlled trial," and "clinical trial." Randomized clinical trials (RCTs) using GSZD were included in the review and meta-analysis. According to heterogeneity, odds ratio and confidence intervals in the pooled RCTs were assessed by a fixed or random model in meta-analysis. Risk of bias was evaluated for all included studies.
Thirteen RCTs met the inclusion criteria and were included in the meta-analysis. All studies evaluated the efficacy of GSZD for treating RA, but the herbal formulations varied since some studies added herbs to the basic GSZD formulation. However, all formulations contained the essential herbs: Guizhi, Shaoyao, and Zhimu. Each RCT included an experimental group (GSZD with or without Western-style medicine) and a control group (either standard Western-style medicines or placebo). When compared to placebo, the GSZD treatment was found to be three to six times more effective than standard Western drugs for some symptoms. Furthermore, only two studies reported any adverse events associated with the GSZD group, whereas several reported serious adverse events in the control groups.
The Traditional Chinese Medicine, GSZD, may have equal or superior effectiveness and safety for treating RA compared to Western RA drugs. It should be considered a viable alternative to Western medicine. However, more long-term research is needed in larger patient groups to better establish its safety and efficacy.
桂枝芍药知母汤(GSZD)是一种用于治疗类风湿性关节炎(RA)的传统中药,其应用历史悠久,且有现代科学研究支持其疗效,但相关研究尚未得到系统评价。因此,本研究利用现有的人体临床试验对GSZD的疗效进行系统综述并开展荟萃分析。
使用英语、韩语和中文等合适语言检索可用数据库。检索所用的关键词为“GSZD”“桂枝”“Guizhi”“芍药”“Shaoyao”“知母”“Anemarrhena Rhizome”“Zhimu”“类风湿性关节炎”“随机”“对照试验”和“临床试验”。使用GSZD的随机临床试验(RCT)纳入本综述和荟萃分析。根据异质性,在荟萃分析中通过固定或随机模型评估汇总RCT中的比值比和置信区间。对所有纳入研究评估偏倚风险。
13项RCT符合纳入标准并纳入荟萃分析。所有研究均评估了GSZD治疗RA的疗效,但草药配方各不相同,因为一些研究在基本的GSZD配方中添加了其他草药。然而,所有配方都包含主要草药:桂枝、芍药和知母。每项RCT均包括一个试验组(GSZD加或不加西药)和一个对照组(标准西药或安慰剂)。与安慰剂相比,发现GSZD治疗在某些症状方面比标准西药有效三至六倍。此外,只有两项研究报告了与GSZD组相关的任何不良事件,而有几项研究报告了对照组中的严重不良事件。
与西方治疗RA的药物相比,中药GSZD在治疗RA方面可能具有同等或更优的有效性和安全性。它应被视为西药的一种可行替代方案。然而,需要在更大的患者群体中进行更多长期研究,以更好地确定其安全性和疗效。